FDA Approves Enhertu for HR+/HER2-low Breast Cancer: Key Trial Results & Insights Breast Cancer 3 Mins Read FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in Treatment Published: February 20, 2025 On…
FDA Approves Mirdametinib: Is this the Breakthrough NF1-PN Patients Have Been Waiting For? Other 3 Mins Read FDA Approves Mirdametinib for NF1-PN: A New Option for Patients Introduction: The FDA has recently approved Mirdametinib (Gomekli) from SpringWorks…
